Literature DB >> 17976187

Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome.

Hussam Ghoti1, Johnny Amer, Asher Winder, Eliezer Rachmilewitz, Eitan Fibach.   

Abstract

Low-risk myelodysplastic syndrome (MDS) is characterized by cytopenia, mainly anemia, because of ineffective hematopoiesis. Some of the patients with ineffective erythropoiesis, with or without ring sideroblasts in their bone marrow, develop severe anemia requiring frequent blood transfusions and consequently develop iron overload. Excess free iron in cells catalyses the generation of reactive oxygen species (ROS) that cause cell and tissue damage. Using flow cytometry techniques, we compared the oxidative status of red blood cells (RBC), platelets and neutrophils in 14 MDS patients with those of normal donors. The results show that ROS were higher while reduced glutathione (GSH) was lower in their RBC and platelets compared with normal cells. In neutrophils, no difference was found in ROS, while the GSH levels were lower. A correlation (r = 0.6) was found between serum ferritin levels of the patients and the ROS in their RBC and platelets. The oxidative stress was ameliorated by a short incubation with the iron-chelators, the deferrioxamine and deferiprone or with antioxidants such as N-acetylcysteine, suggesting that MDS patients might benefit from treatment with iron-chelators and antioxidants.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17976187     DOI: 10.1111/j.1600-0609.2007.00972.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  39 in total

1.  Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging.

Authors:  Emanuela Messa; Sonia Carturan; Chiara Maffè; Marisa Pautasso; Enrico Bracco; Antonella Roetto; Francesca Messa; Francesca Arruga; Ilaria Defilippi; Valentina Rosso; Chiara Zanone; Antonia Rotolo; Elisabetta Greco; Rosa M Pellegrino; Daniele Alberti; Giuseppe Saglio; Daniela Cilloni
Journal:  Haematologica       Date:  2010-06-09       Impact factor: 9.941

Review 2.  Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Authors:  Heather A Leitch
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

3.  Deferiprone reduces amyloid-β and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet.

Authors:  Jaya R P Prasanthi; Matthew Schrag; Bhanu Dasari; Gurdeep Marwarha; April Dickson; Wolff M Kirsch; Othman Ghribi
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

4.  Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes.

Authors:  Hussam Ghoti; Eitan Fibach; Drorit Merkel; Galit Perez-Avraham; Sigal Grisariu; Eliezer A Rachmilewitz
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

Review 5.  Anaerobic storage of red blood cells.

Authors:  Tatsuro Yoshida; Sergey S Shevkoplyas
Journal:  Blood Transfus       Date:  2010-10       Impact factor: 3.443

Review 6.  Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia.

Authors:  Sara Gardenghi; Robert W Grady; Stefano Rivella
Journal:  Hematol Oncol Clin North Am       Date:  2010-10-15       Impact factor: 3.722

Review 7.  Iron overload in myelodysplastic syndromes (MDS).

Authors:  Norbert Gattermann
Journal:  Int J Hematol       Date:  2017-11-25       Impact factor: 2.490

Review 8.  Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia.

Authors:  Viktoria Kuhn; Lukas Diederich; T C Stevenson Keller; Christian M Kramer; Wiebke Lückstädt; Christina Panknin; Tatsiana Suvorava; Brant E Isakson; Malte Kelm; Miriam M Cortese-Krott
Journal:  Antioxid Redox Signal       Date:  2017-01-18       Impact factor: 8.401

9.  Oxidative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome.

Authors:  Yang Jo Chung; Carine Robert; Sheryl M Gough; Feyruz V Rassool; Peter D Aplan
Journal:  Leuk Res       Date:  2013-08-16       Impact factor: 3.156

10.  Kinetics of iron removal by phlebotomy in patients with iron overload after allogeneic hematopoietic cell transplantation.

Authors:  Ann-Kathrin Eisfeld; Rainer Krahl; Nadja Jaekel; Dietger Niederwieser; Haifa Kathrin Al-Ali
Journal:  Am J Blood Res       Date:  2012-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.